Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy [Yahoo! Finance]
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: Yahoo! Finance
price target on Monopar Therapeutics to $142 from $80, while keeping a Strong Buy rating on the shares. The firm thinks that the company's shares can continue to work well into 2026. Earlier in Q2 2025, the company's net loss was $2.5 million (or $0.35 per share), compared to a net loss of $1.7 million (or $0.49 per share) for Q2 2024. Monopar Therapeutics reported that its cash, cash equivalents, and investments totaled $53.3 million, which will support operations through December 31, 2026. Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy This will allow the company to follow its anticipated timeline and execute tasks like filing an NDA for ALXN1840, concluding its Phase 1 imaging/dosimetry trial for MNPR-101-Zr, continuing its Phase 1a therapeutic trial for MNPR-101-Lu, and advancing its preclinical MNPR-101-Ac program into the clinic. Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company that develops therapeu
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]Yahoo! Finance
- Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.MarketBeat
- Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]Seeking Alpha
- Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]Yahoo! Finance
- Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent DevelopmentsGlobeNewswire
MNPR
Earnings
- 11/13/25 - Miss
MNPR
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- MNPR's page on the SEC website